Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases
Background Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune p...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2020-05, Vol.122 (10), p.1518-1524 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1524 |
|---|---|
| container_issue | 10 |
| container_start_page | 1518 |
| container_title | British journal of cancer |
| container_volume | 122 |
| creator | Stremitzer, Stefan Vermeulen, Peter Graver, Shannon Kockx, Mark Dirix, Luc Yang, Dongyun Zhang, Wu Stift, Judith Wrba, Friedrich Gruenberger, Thomas Lenz, Heinz-Josef Scherer, Stefan J. |
| description | Background
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.
Methods
CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated.
Results
One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0–80.4) years, median follow-up 32.2 (5.0–92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60,
P
= 0.001) and OS (36.6 months versus not reached, HR 2.32,
P
= 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85,
P
= 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS.
Conclusions
The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture. |
| doi_str_mv | 10.1038/s41416-020-0812-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7217855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2401742069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-d769200f28955a0d812751fec40d6ef841d4a8d01c76d4537dfc7ca2c96e39223</originalsourceid><addsrcrecordid>eNp1kU1r3DAQhkVpaDbb_oBeiqGXXtyMZFmSL4USmg8I9NKehSKP1wq25EpyQvLrq2XT9AMKAmk0z7ya0UvIWwofKTTqNHHKqaiBQQ2KsvrxBdnQtmE1VUy-JBsAkDV0DI7JSUq3JexAyVfkuGEMWiWaDbm5mufVY7WM6EN-WLAyvq9Gl3JYTB7DFHbOmqnaxXCfx6rcZYy-cn5_dOhzqu5dSdhCRrS5oJO7w1jNmE0qC9NrcjSYKeGbp31Lvp9_-XZ2WV9_vbg6-3xdWy4h170UpVMYmOra1kBfBpItHdBy6AUOitOeG9UDtVL0vG1kP1hpDbOdwKZjrNmSTwfdZb2ZsbeluWgmvUQ3m_igg3H674x3o96FOy0Zlapti8CHJ4EYfqyYsp5dsjhNxmNYk2aNYkJwXv5-S97_g96GNfoynmYcqOQMRFcoeqBsDClFHJ6boaD3DuqDg7o4qPcO6sdS8-7PKZ4rfllWAHYAUkn5HcbfT_9f9SeYMKlS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401742069</pqid></control><display><type>article</type><title>Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Stremitzer, Stefan ; Vermeulen, Peter ; Graver, Shannon ; Kockx, Mark ; Dirix, Luc ; Yang, Dongyun ; Zhang, Wu ; Stift, Judith ; Wrba, Friedrich ; Gruenberger, Thomas ; Lenz, Heinz-Josef ; Scherer, Stefan J.</creator><creatorcontrib>Stremitzer, Stefan ; Vermeulen, Peter ; Graver, Shannon ; Kockx, Mark ; Dirix, Luc ; Yang, Dongyun ; Zhang, Wu ; Stift, Judith ; Wrba, Friedrich ; Gruenberger, Thomas ; Lenz, Heinz-Josef ; Scherer, Stefan J.</creatorcontrib><description>Background
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.
Methods
CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated.
Results
One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0–80.4) years, median follow-up 32.2 (5.0–92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60,
P
= 0.001) and OS (36.6 months versus not reached, HR 2.32,
P
= 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85,
P
= 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS.
Conclusions
The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-0812-z</identifier><identifier>PMID: 32205863</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/546 ; 692/4028/67/1504/1885/1393 ; 692/4028/67/1504/1885/1777 ; 692/53/2422 ; 692/53/2423 ; Adult ; Aged ; Aged, 80 and over ; Angiogenesis ; Bevacizumab ; Bevacizumab - administration & dosage ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Proliferation - drug effects ; Chemotherapy ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Combined Modality Therapy ; Disease-Free Survival ; Drug Resistance ; Epidemiology ; Female ; Growth patterns ; Hepatectomy - methods ; Humans ; Inflammation ; Liver ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Liver Neoplasms - secondary ; Male ; Metastases ; Metastasis ; Middle Aged ; Molecular Medicine ; Monoclonal antibodies ; Neoadjuvant Therapy - methods ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; Oncology ; Patients ; Phenotype ; Phenotypes ; Survival ; Targeted cancer therapy</subject><ispartof>British journal of cancer, 2020-05, Vol.122 (10), p.1518-1524</ispartof><rights>The Author(s), under exclusive licence to Cancer Research UK 2020</rights><rights>The Author(s), under exclusive licence to Cancer Research UK 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-d769200f28955a0d812751fec40d6ef841d4a8d01c76d4537dfc7ca2c96e39223</citedby><cites>FETCH-LOGICAL-c470t-d769200f28955a0d812751fec40d6ef841d4a8d01c76d4537dfc7ca2c96e39223</cites><orcidid>0000-0002-4815-4135</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217855/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217855/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32205863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stremitzer, Stefan</creatorcontrib><creatorcontrib>Vermeulen, Peter</creatorcontrib><creatorcontrib>Graver, Shannon</creatorcontrib><creatorcontrib>Kockx, Mark</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Yang, Dongyun</creatorcontrib><creatorcontrib>Zhang, Wu</creatorcontrib><creatorcontrib>Stift, Judith</creatorcontrib><creatorcontrib>Wrba, Friedrich</creatorcontrib><creatorcontrib>Gruenberger, Thomas</creatorcontrib><creatorcontrib>Lenz, Heinz-Josef</creatorcontrib><creatorcontrib>Scherer, Stefan J.</creatorcontrib><title>Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.
Methods
CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated.
Results
One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0–80.4) years, median follow-up 32.2 (5.0–92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60,
P
= 0.001) and OS (36.6 months versus not reached, HR 2.32,
P
= 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85,
P
= 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS.
Conclusions
The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.</description><subject>692/4028/546</subject><subject>692/4028/67/1504/1885/1393</subject><subject>692/4028/67/1504/1885/1777</subject><subject>692/53/2422</subject><subject>692/53/2423</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis</subject><subject>Bevacizumab</subject><subject>Bevacizumab - administration & dosage</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemotherapy</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Growth patterns</subject><subject>Hepatectomy - methods</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Liver</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Monoclonal antibodies</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Phenotype</subject><subject>Phenotypes</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1r3DAQhkVpaDbb_oBeiqGXXtyMZFmSL4USmg8I9NKehSKP1wq25EpyQvLrq2XT9AMKAmk0z7ya0UvIWwofKTTqNHHKqaiBQQ2KsvrxBdnQtmE1VUy-JBsAkDV0DI7JSUq3JexAyVfkuGEMWiWaDbm5mufVY7WM6EN-WLAyvq9Gl3JYTB7DFHbOmqnaxXCfx6rcZYy-cn5_dOhzqu5dSdhCRrS5oJO7w1jNmE0qC9NrcjSYKeGbp31Lvp9_-XZ2WV9_vbg6-3xdWy4h170UpVMYmOra1kBfBpItHdBy6AUOitOeG9UDtVL0vG1kP1hpDbOdwKZjrNmSTwfdZb2ZsbeluWgmvUQ3m_igg3H674x3o96FOy0Zlapti8CHJ4EYfqyYsp5dsjhNxmNYk2aNYkJwXv5-S97_g96GNfoynmYcqOQMRFcoeqBsDClFHJ6boaD3DuqDg7o4qPcO6sdS8-7PKZ4rfllWAHYAUkn5HcbfT_9f9SeYMKlS</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Stremitzer, Stefan</creator><creator>Vermeulen, Peter</creator><creator>Graver, Shannon</creator><creator>Kockx, Mark</creator><creator>Dirix, Luc</creator><creator>Yang, Dongyun</creator><creator>Zhang, Wu</creator><creator>Stift, Judith</creator><creator>Wrba, Friedrich</creator><creator>Gruenberger, Thomas</creator><creator>Lenz, Heinz-Josef</creator><creator>Scherer, Stefan J.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4815-4135</orcidid></search><sort><creationdate>20200501</creationdate><title>Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases</title><author>Stremitzer, Stefan ; Vermeulen, Peter ; Graver, Shannon ; Kockx, Mark ; Dirix, Luc ; Yang, Dongyun ; Zhang, Wu ; Stift, Judith ; Wrba, Friedrich ; Gruenberger, Thomas ; Lenz, Heinz-Josef ; Scherer, Stefan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-d769200f28955a0d812751fec40d6ef841d4a8d01c76d4537dfc7ca2c96e39223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/4028/546</topic><topic>692/4028/67/1504/1885/1393</topic><topic>692/4028/67/1504/1885/1777</topic><topic>692/53/2422</topic><topic>692/53/2423</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis</topic><topic>Bevacizumab</topic><topic>Bevacizumab - administration & dosage</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemotherapy</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Growth patterns</topic><topic>Hepatectomy - methods</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Liver</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Monoclonal antibodies</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Phenotype</topic><topic>Phenotypes</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stremitzer, Stefan</creatorcontrib><creatorcontrib>Vermeulen, Peter</creatorcontrib><creatorcontrib>Graver, Shannon</creatorcontrib><creatorcontrib>Kockx, Mark</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Yang, Dongyun</creatorcontrib><creatorcontrib>Zhang, Wu</creatorcontrib><creatorcontrib>Stift, Judith</creatorcontrib><creatorcontrib>Wrba, Friedrich</creatorcontrib><creatorcontrib>Gruenberger, Thomas</creatorcontrib><creatorcontrib>Lenz, Heinz-Josef</creatorcontrib><creatorcontrib>Scherer, Stefan J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stremitzer, Stefan</au><au>Vermeulen, Peter</au><au>Graver, Shannon</au><au>Kockx, Mark</au><au>Dirix, Luc</au><au>Yang, Dongyun</au><au>Zhang, Wu</au><au>Stift, Judith</au><au>Wrba, Friedrich</au><au>Gruenberger, Thomas</au><au>Lenz, Heinz-Josef</au><au>Scherer, Stefan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>122</volume><issue>10</issue><spage>1518</spage><epage>1524</epage><pages>1518-1524</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.
Methods
CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated.
Results
One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0–80.4) years, median follow-up 32.2 (5.0–92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60,
P
= 0.001) and OS (36.6 months versus not reached, HR 2.32,
P
= 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85,
P
= 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS.
Conclusions
The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32205863</pmid><doi>10.1038/s41416-020-0812-z</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4815-4135</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2020-05, Vol.122 (10), p.1518-1524 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7217855 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 692/4028/546 692/4028/67/1504/1885/1393 692/4028/67/1504/1885/1777 692/53/2422 692/53/2423 Adult Aged Aged, 80 and over Angiogenesis Bevacizumab Bevacizumab - administration & dosage Biomedical and Life Sciences Biomedicine Cancer Research Cell Proliferation - drug effects Chemotherapy Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Combined Modality Therapy Disease-Free Survival Drug Resistance Epidemiology Female Growth patterns Hepatectomy - methods Humans Inflammation Liver Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - pathology Liver Neoplasms - secondary Male Metastases Metastasis Middle Aged Molecular Medicine Monoclonal antibodies Neoadjuvant Therapy - methods Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Oncology Patients Phenotype Phenotypes Survival Targeted cancer therapy |
| title | Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A22%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20phenotype%20and%20histopathological%20growth%20pattern%20in%20patients%20with%20colorectal%20liver%20metastases&rft.jtitle=British%20journal%20of%20cancer&rft.au=Stremitzer,%20Stefan&rft.date=2020-05-01&rft.volume=122&rft.issue=10&rft.spage=1518&rft.epage=1524&rft.pages=1518-1524&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-0812-z&rft_dat=%3Cproquest_pubme%3E2401742069%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2401742069&rft_id=info:pmid/32205863&rfr_iscdi=true |